Trump tariffs would increase biopharma costs — industry survey
The Trump administration's threatened tariffs on Europe would be painful for the biotech industry, according to data from a survey conducted by the industry's main lobbying group. Of every company...
View ArticleEpicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD
Decades ago, Amber Salzman remembers feeling like there was nothing she could do to help her cousin-in-law with a progressive muscle disease called facioscapulohumeral muscular dystrophy, or FSHD. She...
View ArticleEndpoints Slack interview: Duke's Chatterjee on AI bio, NIH cuts
The Endpoints News Slack chat is back for 2025, and we're starting with a 32-year-old computational biology professor who isn’t afraid to share a hot take or two. Pranam Chatterjee opened his Duke...
View ArticleHumacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer
Plus, news about Tribune Therapeutics and Leap Therapeutics: Humacyte’s $50M offering: The North Carolina biotech is selling 25 million shares at $2.00 apiece, which is nearly 30% lower than its...
View ArticleElevateBio trims workforce by 17%
One of the biotech industry's most well-funded cell and gene therapy companies has laid off employees for the third year in a row. ElevateBio, which raised biotech's largest private funding round in ...
View ArticleWave strengthens case for accelerated approval, with more positive Duchenne data
Wave Life Sciences shared updated results from a Phase 2 trial of its exon-skipping oligonucleotide candidate in Duchenne muscular dystrophy, bolstering its plans to file for accelerated approval next...
View ArticleJ&J touts new survival data for lung cancer combo
Johnson & Johnson released new data suggesting its lung cancer combination Rybrevant and Lazcluze beat AstraZeneca’s Tagrisso on overall survival. In a Phase 3 trial, 56% of patients who took...
View ArticleWhy did radiopharma biotech Actinium hold an investor event at Mar-a-Lago?
Plenty of companies and CEOs have made the pilgrimage to Donald Trump's Mar-a-Lago resort to meet with the president. But small-cap biotech Actinium Pharmaceuticals is one of the few to hold a public...
View ArticleExelixis’ cancer drug wins approval for neuroendocrine tumors
The FDA has approved Exelixis' cancer drug Cabometyx to treat advanced neuroendocrine tumors inside and outside of the pancreas, marking two new indications for the company’s primary source of revenue....
View ArticleFDA critiques 'misleading' Taiho promotion of bile duct cancer drug
The FDA is taking issue with a promotional website from Taiho Oncology, alleging it misleadingly describes the benefits of its bile duct cancer drug Lytgobi, which won accelerated approval in 2022. The
View ArticleFDA approves Soleno’s rare disease drug for Prader-Willi syndrome
The FDA on Wednesday approved Soleno Therapeutics' new drug designed to treat the worst symptom of a debilitating rare disease known as Prader-Willi syndrome. Regulators approved diazoxide choline...
View ArticleAlcon takes majority stake in Aurion, changes CEOs
Eye giant Alcon said Wednesday it acquired a majority stake in cell therapy startup Aurion and replaced CEO Greg Kunst, the latest twist in a struggle for power between the two companies. The...
View ArticleGalatea Bio gets $25M to map genetic diversity of 10 million people, help...
A Miami startup looking to sequence the genetic diversity of 10 million people this decade has pulled in $25 million in total funding. Galatea Bio wants to create a global biobank that can be used ...
View ArticleCandel to focus on non-squamous lung cancer following new survival data
Candel Therapeutics said Wednesday that new data on its viral immunotherapy showed only a marginal improvement in survival of progressive lung cancer patients compared with an earlier cut from the same...
View ArticleAI scribes reduce burnout, but financial returns unclear — report
Despite cutting down on burnout, AI scribes have yet to clearly prove they save clinicians time and show financial returns, a new report found. For the report, the Peterson Health Technology Institute...
View ArticleMiga Health co-founder shares why he turned down new funding
Last year, Miga Health, a virtual cardiovascular care company, told investors it wasn't going to raise more money and would stop running a central part of its business, transitioning its thousands of...
View ArticleHHS plans to cut 10,000 more staffers in major downsizing
The Department of Health and Human Services on Thursday announced major plans to downsize the department as part of a major reorganization built around Secretary Robert F. Kennedy Jr.'s "Make America...
View ArticleNkarta to lay off 34% of staff; Savara’s debt financing deal
Plus, news about Bicycle Therapeutics, Kelso Pharma, Arbutus Biopharma, Ascletis Pharma, Alvotech and Xbrane: Nkarta axes 34% of staff: The cell therapy maker said the layoffs of 53 workers would help ...
View ArticleWhat happened to Miga Health
My latest story is one I don’t get the chance to write often — maybe ever. When I first heard some murmurs that Miga Health, a virtual cardiovascular care company, had stopped taking patients, I...
View ArticleEquillium says graft-versus-host drug fails Phase 3, stock dives
A penny stock biotech reported that its acute graft-versus-host disease drug failed a late-stage trial, but it still plans to seek accelerated approval. Equillium said Thursday that itolizumab did not...
View Article